When the NF1 gene was discovered in 1990, it was quickly learned that the gene product functions as a regulator of a protein called Ras. Ras is a key component of a cell signaling pathway that ...
Panelists discuss how mutations in the NF1 gene lead to loss of neurofibromin function, resulting in hyperactivation of the RAS/MAPK and PI3K/AKT/mTOR pathways, and how this molecular dysregulation ...
Erasca, Inc. presents promising preclinical data on ERAS-0015 and ERAS-4001 targeting RAS/MAPK pathway cancers at AACR meeting. Erasca, Inc. presented new preclinical data at the American Association ...
Data suggest rigosertib stimulates an anti-cancer immune response via NLRP3 activation, providing mechanistic support for clinical trials of rigosertib-checkpoint inhibitor combinations Data reveal ...
Research and development (R&D) expenses: R&D expenses were $35.1 million for the third quarter of 2025 compared to $17.9 million for the third quarter of 2024. The increase in expenses was primarily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback